• Ascension, a major U.S. healthcare system, joins SAPPHIRE Study
• SAPPHIRE Study aims to assess Artrya's Salix AI platform and Plaque Dispersion Score
• Study to focus on improving care for women with coronary artery disease

Artrya Limited, a medical technology company commercialising its Salix AI-powered cloud platform for the assessment and management of coronary artery disease, has announced that Ascension, one of the largest non-profit and Catholic health systems in the U.S., has agreed to participate in the U.S. multi-centre clinical SAPPHIRE Study. Ascension, based in St. Louis, Missouri, is the sixth largest non-profit system in the U.S. and operates 94 hospitals across 16 states and the District of Columbia. The Ascension Cardiovascular Research Institute, part of the Ascension Clinical Research Institute, has nearly 3,000 active or approved studies at any time. The addition of Ascension provides another major U.S. healthcare system with deep research and clinical trial capabilities to the SAPPHIRE Study, alongside Mass General Brigham, Piedmont Healthcare, and Huntsville Hospital Heart Center. The SAPPHIRE Study aims to evaluate the clinical and prognostic value of Artrya's Salix Plaque Analysis and its proprietary Plaque Dispersion Score (PDS), with a strong focus on improving care for women, 64% of whom who die from coronary artery disease show no prior symptoms. Artrya is on track to launch the SAPPHIRE Study in early 2026.

Artrya is accelerating its activities with the remaining centres expected to be involved in the SAPPHIRE Study and finalising the study protocols as it prepares to launch the study in early 2026.